Allan H. Friedman, MD

Related Content

Services

• Brain Tumors

Chief, Division of Neurosurgery in the Department of Surgery
Co-Director, Neuro-Oncology Program

• Surgery / Neurosurgery
• Medicine / Neurology

Address:
DUMC 3807
Durham, NC 27710

Appointment Telephone:
(919) 681-6421

Office Telephone:
(919) 681-6421

Fax Telephone:
(919) 681-7872

• M.D., University of Illinois, 1974

• Neurosurgery, Duke University Medical Center, North Carolina, 1974-1980
• University of Western Ontario, Canada, 1980

Clinical Interests:
Brain tumors, skull base tumors, peripheral nerve surgery, pituitary tumors, cerebrovascular disease

Research Interests:
At the present time, I am participating in collaborative research in the areas of primary malignant brain tumors, epilepsy and subarachnoid hemorrhage.

Primary malignant brain tumors are increasing in frequency.  Patients harboring glioblastoma, the most malignant primary brain tumor, have a life expectancy of less than one year.  In colloboration with the Division of Neurology and the Department of Pathology, clinical and laboratory trials have been initiated to identify better treatment for this condition.  At present, trials of monoclonal antibodies and novel chemotherapeutic agents are being carried out.

Although physicians have been interested in seizures since the time of Hippocrates, the origin of seizures remains obscure.  At Duke University we have treated approximately thirty seizure patients a year by removing abnormal portions of brain.  Tissue from these resections is being analyzed for genetics and receptor abnormalities.  Positron emission tomography and magnetic resonance imaging are being used to ferret out the origin of the patient's seizures.

Approximately 28,000 patients each year suffer a ruptured intracranial aneurysm.  Approximately ten percent of these patients have a genetic predisposition to forming intracranial aneurysms.  In conjunction with the Division of Neurology, we are screening candidate genes searching for the cause of intracranial aneurysms.

Representative Publications:
Friedman AH, Gray L. Clinical and radiological findings of spinal dural arteriovenous fistula. Perspectives in Neurological Surgery 3:1-15, 1992. (1992)

Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, Friedman AH, Bigner DD, Bigner SH, McLendon RE. Molecular markers of prognosis in astrocytic tumors. Cancer. 2002 May 15;94(10):2688-97. (2002) Abstract

Husain AM, Mendez M, Friedman AH. Intractable epilepsy following radiosurgery for arteriovenous malformation. J Neurosurg. 2001 Nov;95(5):888-92. (2001) Abstract

Little KM, Friedman AH, Fukushima T. Surgical approaches to pineal region tumors. J Neurooncol. 2001 Sep;54(3):287-99. (2001) Abstract

Little K, Friedman AH:  Postherpetic Neuralgia, in Wilkins R (ed) Neurosurgery, 3rd edition, (In press). (Book chapter) (2002)

New KC and Friedman AH. "Pre- and Post-Operative Management of a Patient with a Ruptured Aneurysm" in Neurosurgery, 3rd edition, eds Rengachary SS and Ellenbogen R.  McGraw-Hill, New York, (in press). (Book chapter) (2002)

Cokgor I, Friedman AH, Friedman HS. Current options for the treatment of neoplastic meningitis. J Neurooncol. 2002 Oct;60(1):79-88. (2002) Abstract

Friedman AH, Nashold BS Jr, Bronec PR. Dorsal root entry zone lesions for the treatment of brachial plexus avulsion injuries: a follow-up study. Neurosurgery 22:369-373, 1988. (1988)

Friedman AH, Nunley JA II, Goldner RD, Oakes WJ, Goldner JL, Urbaniak JR. Nerve transposition for the restoration of elbow flexion following brachial plexus avulsion injuries. J Neurosurg 72:59-64, 1990. (1990)

Gabriel, E.M., Villavicencio, A.T., Friedman, A.H.: Evaluation and Surgical Repair of Brachial Plexus Injuries. Seminars in Neurosurgery 12 (1):29-48, 2001. (2001)

Friedman, A.H., Quinn, J.A., Tourt-Uhlig, S., Rich, J.N., Stewart, E.S., Affronti, M.L., Provenzale, J., McLendon, R., Gururangan, S., Buchanan, W., Colvin, O.M., Bigner, D.D., Beason, R., Sampson, J., Haglund, M., Miller, L., and Friedman, H.S.: Phase I trial of CPT-11 plus BCNU in malignant glioma. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. In press, 2001. (2001)

McGirt MJ, Lynch JR, Blessing R, Warner DS, Friedman AH, Laskowitz DT. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2002 Nov;51(5):1128-35. (2002) Abstract

McGirt MJ, Villavicencio AT, Bulsara KR, Friedman HS, Friedman AH. Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. J Neurosurg. 2002 May;96(5):941-5. (2002) Abstract

Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncol. 2001 Oct;3(4):246-50. (2001) Abstract

Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002 Mar 1;20(5):1389-97. (2002) Abstract

Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, McLendon RE, Friedman AH, Tourt-Uhlig S, Miller LL, Friedman HS. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-oncol. 2002 Apr;4(2):102-8. (2002) Abstract

Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery. 2002 Jan;50(1):158-64; discussion 164-6. (2002) Abstract

Cokgor I, Akabani G, Friedman HS, Friedman AH, Zalutsky MR, Zehngebot LM, Provenzale JM, Guy CD, Wikstrand CJ, Bigner DD. Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study. Cancer. 2001 May 1;91(9):1809-13. (2001) Abstract

Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 1;20(9):2277-83. (2002) Abstract

Bulsara KR, Fukushima T, Friedman AH.  Management of malignant tumors of the anterior skull base:  experience with 76 patients.  Neurosurg Focus 13(4):1-11, 2002. (2002)

Friedman AH, Alexander MJ:  Arterial dissections, in Wilkins R (ed). Neurosurgery, 3rd edition, Chapter 212 (In press) (Book chapter) (2002)

Alexander MJ, Friedman AH:  Subarachnoid hemorrhage of unknown etiology, in Wilkins R (ed). Neurosurgery, 3rd edition, Chapter 232 (In press). (Book chapter) (2002)

New KC and Friedman AH. "Intramedullary tumors and tumors of the cauda equina" in Principles of Neurosurgery, 2nd edition, eds. Rengachary SS and Ellenbogen R.  Elsevier Science Ltd, London, (in press). (Book chapter) (2002)

Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Brain Tumors in Mice Are Susceptible to Blockade of Epidermal Growth Factor Receptor (EGFR) with the Oral, Specific, EGFR-Tyrosine Kinase Inhibitor ZD1839 (Iressa). Clin Cancer Res. 2002 Nov;8(11):3496-502. (2002) Abstract

Sampson JH, Reardon DA, Friedman AH, Friedman HS, Coleman RE, McLendon RE, Pastan I, Bigner DD. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro-oncol. 2005 Jan;7(1):90-6. (2005) Abstract

Little KM, Zomorodi AR, Selznick LA, Friedman AH. An eclectic history of peripheral nerve surgery. Neurosurg Clin N Am. 2004 Apr;15(2):109-23. (2004) Abstract

Patil PG, Friedman AH. Surgical exposure of the sciatic nerve in the gluteal region: anatomic and historical comparison of two approaches. Neurosurgery. 2005 Jan;56(1 Suppl):165-71; discussion 165-71. (2005) Abstract

Little KM, Friedman AH, Sampson JH, Wanibuchi M, Fukushima T. Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients. Neurosurgery. 2005 Mar;56(3):546-59; discussion 546-59. (2005) Abstract

Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006 Jan 1;24(1):115-22. (2006) Abstract

Sampson JH, Akabani G, Friedman AH, Bigner D, Kunwar S, Berger MS, Bankiewicz KS. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus. 2006;20(4):E14. (2006) Abstract

Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE 2nd, Cahill A, Friedman HS, Vredenburgh JJ. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro-oncol. 2007 Jan;9(1):70-4. (2007) Abstract